Barish Ozdamar focuses on intellectual property disputes and IP portfolio strategy/development in the biotechnology, pharmaceutical, and medical device industries. His practice covers a range of technical areas, including precision medicine, gene therapy and delivery vehicles (e.g., CRISPR, AAV, and LNPs), antibodies, vaccines and other biologics, small molecule therapeutics, diagnostics (including cell-free DNA-based applications), and next-generation sequencing technologies. Dr. Ozdamar has extensive experience representing life science clients in District Court litigation, Inter Partes Review proceedings, and arbitration. He also provides counsel to clients in global transactional and diligence matters relating to IP portfolio development, freedom-to-operate/landscape analysis, licensing, enforcement, and valuation/monetization in the context of mergers & acquisitions, as well as portfolio company investment strategies.

Dr. Ozdamar’s technical training is in the area of molecular biology and genetics. Prior to his Post-Doctoral Fellowship at Cornell University Weill Medical College, Dr. Ozdamar completed his Ph.D. studies at the University of Toronto, during which time he published several papers directed to cancer biology and molecular pathways regulating tumor metastasis. Dr. Ozdamar’s publication record includes four authorships in the journal Science.


  • Obtained a favorable pre-trial result for our client, a large medical device company, in connection with a gene expression platform.
  • Successful District Court representation of a leading medical diagnostic company in a matter relating to fetal genetic testing.
  • Desired outcome for multi-national pharmaceutical client faced with an infringement suit relating to antibody and screening technologies.
  • Represented and obtained a favorable pre-trial outcome for a large biotechnology company challenged by multiple generic biologic entrants against an antibody product.
  • Successful representation of a large pharmaceutical client in an ANDA litigation relating to a small-molecule anti-cancer compound.
  • Desired outcome for a large pharmaceutical client in Swiss arbitration proceedings relating to genetic screening technologies.


  • Selected for inclusion in Best Lawyers: Ones to Watch for intellectual property law (2024).
  • Canadian Institutes of Health Research Post-Doctoral Fellowship.
  • Heart and Stroke Foundation of Canada Post-Doctoral Fellowship.
  • Canadian Institutes of Health Research Doctoral Award.

Insights & News


  • Education

    • JD, Fordham University School of Law, 2011

    • Post-Doctoral Fellow, Biochemistry, Cornell University Weill Graduate School of Medical Sciences, 2007

    • Post-Doctoral Fellow, Cell Biology, 2006

      The Hospital for Sick Children, Toronto, Canada
    • PhD, Medical Genetics, University of Toronto, 2005

      Samuel Lunenfeld Research Institute, Mt. Sinai Hospital
    • BSc (Hons), York University, 1998

  • Admissions

    • New York

    • US Patent and Trademark Office

  • Languages

    • French

    • Turkish



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.